Therapeutic Areas
Cardiovascular Disease Clinical Research
Driving Successful Outcomes for Cardiovascular Trials
As leading life-shortening illnesses, cardiovascular diseases are critical to prevent and treat immediately in patients around the world. That is why Veristat has built a team of scientific-minded experts who have supported more than 120 cardiovascular Phase I-IV projects in a broad range of cardiac specialties.
Our experience includes drugs, biologics, and diagnostics. Our diverse trial background, coupled with our knowledgeable and experienced teams, allow us to confidently handle the most complex trials and patient populations.
+0
Cardiovascular Projects
0%
in Rare/Ultra-Rare Indications
0%
Marketing Application Approval Success Rate
Specialized Expertise from Consultation to Beyond Submission
Our solutions span the entire clinical development life-cycle - and are offered as a comprehensive, all-inclusive solution or as functional support. We provide strategic guidance for informed decision-making, operational support to mitigate trial risks, the statistical knowledge to prove safety and efficacy, the medical oversight to ensure patient safety, and the regulatory expertise to achieve approval success:
- Marketing Application Preparation and Publishing
- Post-Market Pharmacovigilance Ensures Safety
- Marketing Application Preparation and Publishing
- Post-Market Pharmacovigilance Ensures Safety
Cardiovascular Highlights
Therapeutic Categories |
|
---|---|
Acute Coronary Syndrome | Hypertension |
Atherosclerosis | STEMI and Non-ST |
Heart Failure | Stroke |
Therapeutic Categories |
|
---|---|
Abdominal Aortic Aneurysm (AAA) | Intravascular IV Catheter placement |
Aortic Aneurysm | Ischemic Heart Disease, Detection of CAD |
Heart Failure | Non-ST Elevation Myocardial Infarction (NSTEMI) |
Hemostasis, surgical bleeding, for spine, liver, vascular or soft tissue surgery | Vascular Access Graft |
Download the Case Study: Writing Multiple Marketing Applications Simultaneously Under a Time Crunch
Learn how our medical writing team worked with the sponsor to write these marketing applications in an accelerated timeline since the product received Orphan Drug Designation in the US and EU and Priority Review status in Canada.
Download Now